Combivent Dosage & Drug Information

Concise Prescribing Info Bahasa Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Side Effects Drug Interactions Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Per unit dose vial (UDV) Ipratropium Br 0.52 mg, salbutamol sulphate 3.01 mg

Indications/Uses

Management of reversible bronchospasm associated w/ obstructive pulmonary diseases & acute asthma attack in patients who require more than a single bronchodilator.

Click to view Combivent detailed prescribing information

Dosage/Direction for Use

Acute attack 1 unit dose vial, may be increased to 2 unit dose vial in severe cases. Maintenance: 1 unit dose vial 3-4 times daily.

Click to view Combivent detailed prescribing information

Overdosage

View Combivent overdosage for action to be taken in the event of an overdose.

Contraindications

Hypersensitivity to atropine, its derivatives or to any component of Combivent. Hypertrophic obstructive cardiomyopathy or tachyarrhythmia.

Click to view Combivent detailed prescribing information

Special Precautions

Hypersensitivity. Discontinue immediately if paradoxical bronchospasm occurs. Avoid contact w/ the eyes. Patients predisposed to glaucoma, insufficiently controlled DM, recent MI, severe organic heart or vascular disorders, hyperthyroidism, phaeochromocytoma, risk of narrow-angle glaucoma, prostatic hypertrophy or bladder-neck obstruction. Patients w/ underlying severe heart disease eg, ischaemic heart disease, arrhythmia or severe heart failure. Monitor serum K levels. Cystic fibrosis. Acute, rapidly worsening dyspnoea. Avoid prolonged use. Hepatic or renal insufficiency. May impair ability to drive or operate machinery. Pregnancy & lactation.

Click to view Combivent detailed prescribing information

Use In Pregnancy & Lactation

Click to view Combivent detailed prescribing information

Adverse Reactions

Headache, throat irritation, cough, dry mouth, GI motility disorders (eg, constipation, diarrhea & vomiting), nausea & dizziness.

Drug Interactions

Chronic co-administration of Combivent w/ other anticholinergic drugs. Increased side effects w/ xanthine derivatives, β-adrenergics & anticholinergics. Increased hypokalemia w/ digoxin, xanthine derivatives, glucocorticosteroids & diuretics. Reduced bronchodilator effect w/ β-blockers. Enhanced β-adrenergic effects by MAOIs or TCAs. Increased CV effects w/ halothane, trichloroethylene & enflurane.

Click to view Combivent detailed prescribing information

Storage

View Combivent storage conditions for details to ensure optimal shelf-life.

Description

View Combivent description for details of the chemical structure and excipients (inactive components).

Action

View Combivent mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Antiasthmatic & COPD Preparations

ATC Classification

R03AL02 - salbutamol and ipratropium bromide ; Belongs to the class of combination of adrenergics with anticholinergics, that may also include a corticosteroid. Used in the treatment of obstructive airway diseases.

Regulatory Classification

Presentation/Packing

Form

Combivent inhalation soln

Packing/Price

(unit dose vial) 2.5 mL x 20 × 1's

Combivent

ipratropium bromide + salbutamol

Manufacturer:

Boehringer Ingelheim